According to USFDA, the Form 483 is issued to a firm management if there are violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The FDA Form 483 notifies the company’s management of objectionable conditions.
Meanwhile, in a statement the drug firm said that it confident of addressing observations raised, and will work with FDA to resolve them at earliest.
The US agency had inspected the facility from July 3 To July 11, 2023.
Earlier this week, the Mumbai based Lupin said it has received Establishment Inspection Report (EIR) from the US health regulator for its Pithampur Unit-2 facility which manufactures oral solids and ophthalmic dosage forms.
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).”This is a significant milestone as we build back our reputation of being best-in-class in quality and compliance. We look forward to new product approvals and launches, especially ophthalmic products from this facility now,” Lupin Managing Director Nilesh Gupta stated.The US Food and Drug Administration issues an EIR on closure of an inspection of an establishment that is the subject of an FDA or FDA-contracted scrutiny.
As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
